{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:14:01Z","timestamp":1785438841559,"version":"3.56.0"},"reference-count":11,"publisher":"Wiley","issue":"28","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["214794"],"award-info":[{"award-number":["214794"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Real\u2010world evidence is increasingly used to guide treatment and regulatory decisions for non\u2010small cell lung cancer (NSCLC). Real\u2010world treatment patterns and clinical outcomes among patients with advanced\/metastatic NSCLC in France, Germany, Italy, Spain, and the UK (EU5) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective physician\u2010completed patient chart review assessed treatment patterns (regimen, duration of treatment [DOT], time to discontinuation), and clinical outcomes (duration of response [DOR], progression\u2010free survival [PFS], and overall survival [OS]) of patients with stage IIIB\/C or IV NSCLC who received pembrolizumab\u2010based first\u2010line induction chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 322 patients were included; at first\u2010line maintenance (1LM), 92% had stage IV NSCLC, 68% had nonsquamous histology, and 89% had no central nervous system (CNS)\/brain metastasis. The two most common 1LM regimens were pembrolizumab monotherapy (76% overall) and pembrolizumab + pemetrexed (21% overall). Docetaxel monotherapy was the most common second\u2010line regimen in all countries except Germany (54% overall). For 1LM therapy, the overall median DOT and DOR were 5 and 10\u2009months, respectively; PFS was 7\u2009months and OS was 8\u2009months. Germany had a longer duration of each outcome except for DOR which was longer in Spain. Clinical outcomes were generally poorer for patients with squamous histology and CNS\/brain metastases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrated differences in treatment patterns and clinical outcomes in NSCLC across the EU5 and patient subgroups. Improved survival was generally associated with response to first\u2010line therapy, nonsquamous histology, and CNS\/brain metastases absence. These real\u2010world data provide valuable insights which may aid treatment decision\u2010making and clinical trial design.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15069","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T05:39:37Z","timestamp":1692337177000},"page":"2846-2858","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real\u2010world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced\/metastatic non\u2010small cell lung cancer in the <scp>EU5<\/scp>"],"prefix":"10.1111","volume":"14","author":[{"given":"Alexander","family":"Slowley","sequence":"first","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelesitse","family":"Phiri","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjit K.","family":"Multani","sequence":"additional","affiliation":[{"name":"IQVIA  Falls Church Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Casey","sequence":"additional","affiliation":[{"name":"IQVIA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Mpima","sequence":"additional","affiliation":[{"name":"IQVIA  Wayne Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yasuda","sequence":"additional","affiliation":[{"name":"IQVIA  Wayne Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi\u2010Chang","family":"Chen","sequence":"additional","affiliation":[{"name":"IQVIA  Wayne Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fil","family":"Manuguid","sequence":"additional","affiliation":[{"name":"IQVIA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Chao","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Aziez","sequence":"additional","affiliation":[{"name":"GSK  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly F.","family":"Bell","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stojadinovic","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00520-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0230"},{"key":"e_1_2_10_6_1","first-page":"296","article-title":"Real\u2010world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non\u2010small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors","volume":"39","author":"Hogea C","year":"2021","journal-title":"Clin Oncol"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09674-2"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1101"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1102"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3543-7"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:26:02Z","timestamp":1696202762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":11,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/1759-7714.15069"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15069","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"2023-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}